I want to mention as well that with the new tax laws in France ... specific here or is it a way for Sanofi to maybe be more ...

Sanofi and Sudair Pharma Company (SPC ... Sudair Pharma’s factories, the dedicated factory for oral & injectable medicines of oncology & high-potent formulations and the general factory for specialty ...

Third quarter 2024 revenues increased 11% to $3.72 billion versus third quarter 2023Third quarter 2024 Dupixent® global net sales(recorded by ...

We assume a 7.5% cost of equity and 15% long-term tax rate. We still see a potential ... served it well thus far (Bayer/Eylea, Sanofi/immunology and oncology drugs, Teva/pain drug fasinumab ...

Dr. Reddy's Laboratories Limited ( NYSE: RDY) Q2 2025 Earnings Conference Call November 5, 2024 9:00 AM ET Richa Periwal - Head of Investor Relations MV Narasimham - Chief Financial Officer Erez ...

GSK suffered a loss after tax of £58 million ($75 million ... vaccine sales and reflected successful new product launches in oncology and HIV," chief executive Emma Walmsley said in the earnings ...

The Indo US Bridging RARE Summit 2024 will spotlight the urgent need for cross-border collaborations to address disparities in rare disease treatment by bringing together patient advocates, clinicians ...

We take a look at the company's story, from its creation as a merger of two equals, to its recent major restructuring and its drives in cutting-edge oncology and COVID-19. In 1998, Europe’s ...

Canada also encouraged industry's R&D with generous tax credits. Multinational pharmaceutical ... Novartis, Pfizer, Roche, Sanofi Aventis and Sanofi Pasteur. He has been closely involved in ...

Janney Montgomery Scott LLC lessened its stake in Sanofi (NASDAQ:SNY – Free Report) by 0.3% in the third quarter, according ...

However, VIR also pivoted to oncology, discontinuing vaccines and viral immunotherapy, and partnered with Sanofi to leverage its PRO-XTEN platform for T-cell engagers. The strategic shift includes ...